Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.

Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P, Pintor C, Cappa M.

J Clin Endocrinol Metab. 1995 Feb;80(2):674-8.

PMID:
7852535
2.

The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.

Loche S, Cambiaso P, Merola B, Colao A, Faedda A, Imbimbo BP, Deghenghi R, Lombardi G, Cappa M.

J Clin Endocrinol Metab. 1995 Sep;80(9):2692-6.

PMID:
7673411
3.

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.

Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenhaerts V, Deghenghi R, Camanni F, Ghigo E.

J Clin Endocrinol Metab. 1995 Apr;80(4):1090-4.

PMID:
7714074
4.

Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.

Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.

J Endocrinol Invest. 1998 Sep;21(8):494-500.

PMID:
9801989
6.

Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.

Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E.

Peptides. 1997;18(6):885-91.

PMID:
9285939
7.

Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.

Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E.

J Endocrinol Invest. 1997 Mar;20(3):122-7.

PMID:
9186817
8.

Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.

Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E.

J Clin Endocrinol Metab. 2001 Mar;86(3):1169-74.

PMID:
11238504
9.

Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents.

Laron Z, Bowers CY, Hirsch D, Almonte AS, Pelz M, Keret R, Gil-Ad I.

Acta Endocrinol (Copenh). 1993 Nov;129(5):424-6.

PMID:
8279223
10.

The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.

Bartolotta E, Bellone J, Aimaretti G, Arvat E, Benso L, Deghenghi R, Camanni F, Ghigo E.

J Pediatr Endocrinol Metab. 1997 Sep-Oct;10(5):491-7.

PMID:
9401905
11.

The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.

Arvat E, Ramunni J, Bellone J, Di Vito L, Baffoni C, Broglio F, Deghenghi R, Bartolotta E, Ghigo E.

Eur J Endocrinol. 1997 Dec;137(6):635-42.

13.

Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.

Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.

Clin Endocrinol (Oxf). 1997 Oct;47(4):495-500.

PMID:
9404449
14.

Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.

Grottoli S, Maccario M, Procopio M, Oleandri SE, Arvat E, Gianotti L, Deghenghi R, Camanni F, Ghigo E.

Eur J Endocrinol. 1996 Dec;135(6):678-82.

PMID:
9025712
15.

The growth hormone response to hexarelin in patients with Prader-Willi syndrome.

Cappa M, Raguso G, Palmiotto T, Faedda A, Gurreri F, Neri G, Deghenghi R, Loche S.

J Endocrinol Invest. 1998 Sep;21(8):501-5.

PMID:
9801990
16.

Interaction of the growth hormone releasing peptide hexarelin with somatostatin.

Massoud AF, Hindmarsh PC, Brook CG.

Clin Endocrinol (Oxf). 1997 Nov;47(5):537-47.

PMID:
9425393
17.

Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.

Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E.

Metabolism. 1997 Jan;46(1):83-8.

PMID:
9005975
18.

Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.

Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F.

J Clin Endocrinol Metab. 1997 Aug;82(8):2439-44.

PMID:
9253314
19.

Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.

Massoud AF, Hindmarsh PC, Brook CG.

J Clin Endocrinol Metab. 1996 Dec;81(12):4338-41.

PMID:
8954038
20.

Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.

Cappa M, Setzu S, Bernardini S, Carta D, Federici G, Grossi A, Loche S.

J Endocrinol Invest. 1995 Nov;18(10):762-6.

PMID:
8787952

Supplemental Content

Support Center